Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD1801 in NASH and Liver Fibrosis With T2DM or Pre-Diabetes
NCT05623189Phase 2Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Dec 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of berberine ursodeoxycholate in Nonalcoholic steatohepatitis (NASH), sponsored by HighTide Therapeutics, Inc.. Started Dec 2022; status: completed.
02
Drugs
berberine ursodeoxycholate
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05623189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623189.